Vivace Therapeutics, a company that develops cancer treatments, announced on July 30, 2025, that the U.S. Food and Drug Administration (FDA) has granted its experimental drug, VT3989, an “Orphan Drug Designation” (ODD) to treat mesothelioma, a rare and aggressive form of cancer.VT3989 is a TEAD inhibitor. It works by blocking…